Search This Blog

Thursday, May 31, 2018

Tonix says Phase 2 study shows Tonmya reduces PTSD symptoms


Tonix Pharmaceuticals presented data from the Phase 2 AtEase study of Tonmya for the treatment posttraumatic stress disorder. The presentation focused on the rationale for including suicidal individuals in the clinical trial of a treatment for PTSD. “There are several examples in major psychiatric disorders in which pharmacological treatment of the underlying disorder may decrease suicidal behaviors,” said Gregory Sullivan, M.D., Chief Medical Officer of Tonix. “Individuals with military-related PTSD have an elevated risk for suicidal behaviors, and it was hypothesized that addressing underlying PTSD with Tonmya might have an impact on reducing suicidal behaviors. Suicidal individuals were included in the AtEase study as it provided for a more representative sample of the condition for evaluating the efficacy Tonmya 2.8 mg and 5.6 mg as a potential treatment for military-related PTSD.” “Taken nightly at bedtime and absorbed by a sublingual route, Tonmya is believed to reduce PTSD symptoms through improvement in sleep quality, potentially also addressing suicidal behaviors via upstream effects on sleep improvement,” Dr. Sullivan continued “While rates of suicidal ideation and behaviors were not high enough to allow meaningful statistical analyses in AtEase, these data, combined with other datasets acquired by similar methodology, may provide important new information and insights leading to better prediction of, and interventions to prevent, suicides in PTSD.”

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.